Cure trials hold above twenty-one thousand
The cure engine remains immense: 21,174 active trials, with 36 new cure research items and 21 new wire signals in the last 24 hours. On the disease side, the most concrete readout is still clinical: Tiziana says intranasal foralumab reduced brain inflammation in a third multiple system atrophy patient, while oral GLP-1 data continue to show meaningful weight and A1c gains in older adults with obesity. Around that, the system is widening—new microbial bioprospecting work in Brazil’s Blue Amazon, another B-cell drug milestone in IgA nephropathy, and a broader FDA calendar suggest the pipeline is not slowing. The window is still open.
Tiziana Life Sciences reported reduced brain inflammation in a third multiple system atrophy patient treated with intranasal foralumab, extending an emerging clinical signal.
If the signal holds, it matters because neuroinflammation, kidney autoimmunity, and metabolic disease are all still large, unsolved burdens; if it fails, the cost is more time spent on hopeful but unproven mechanisms.
Watch whether the foralumab and GLP-1 signals replicate, while FDA decisions and new discovery work over the next weeks determine whether these isolated readouts become durable progress.